Nuvation Bio Inc. (NUVB) Amends Protocol on Safusidenib Trials in Astrocytoma

Nuvation Bio Inc. (NYSE:NUVB) is one of the best cancer stocks to invest in now. On February 9, Nuvation Bio Inc. (NYSE:NUVB) finalized a protocol amendment to an ongoing global SIGMA study of safusidenib. The company is evaluating the efficacy and safety of safusidenib in patients with high-risk or high-grade IDH1-mutant astrocytoma. Nuvation Bio Inc. (NUVB) Amends Protocol on Safusidenib Trials in Astrocytoma The amended protocol expands patient eligibility in the registration portion of the trial. It ...